Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
HCXT-2001 in Psoriasis: NCT07792928 Clinical Landscape Report 2026
9 min read
HCXT-2001 in Psoriasis: NCT07792928 Clinical Landscape Report 2026
11 September 2026
NCT07792928 clinical landscape for Psoriasis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Lenvatinib mesylate in Locally Advanced Clear Cell Renal Cell Carcinoma: NCT07741617 Clinical Landscape Report 2026
9 min read
Lenvatinib mesylate in Locally Advanced Clear Cell Renal Cell Carcinoma: NCT07741617 Clinical Landscape Report 2026
11 September 2026
NCT07741617 clinical landscape for Locally Advanced Clear Cell Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and develo…
Read →
Zoldonrasib in Pancreatic adenocarcinoma metastatic: NCT07805954 Clinical Landscape Report 2026
9 min read
Zoldonrasib in Pancreatic adenocarcinoma metastatic: NCT07805954 Clinical Landscape Report 2026
11 September 2026
NCT07805954 clinical landscape for Pancreatic adenocarcinoma metastatic: endpoints, sponsor, phase, geography, readouts, asset context and development white…
Read →
Risvutatug Rezetecan in Metastatic castration-resistant prostate cancer: NCT07802704 Clinical Landscape Report 2026
9 min read
Risvutatug Rezetecan in Metastatic castration-resistant prostate cancer: NCT07802704 Clinical Landscape Report 2026
11 September 2026
NCT07802704 clinical landscape for Metastatic castration-resistant prostate cancer: endpoints, sponsor, phase, geography, readouts, asset context and develop…
Read →
ABBV-253 in Ovarian Cancer: NCT07807956 Clinical Landscape Report 2026
9 min read
ABBV-253 in Ovarian Cancer: NCT07807956 Clinical Landscape Report 2026
11 September 2026
NCT07807956 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Anlotinib Dihydrochloride in EGFR-mutated non-small Cell Lung Cancer: NCT07807722 Clinical Landscape Report 2026
9 min read
Anlotinib Dihydrochloride in EGFR-mutated non-small Cell Lung Cancer: NCT07807722 Clinical Landscape Report 2026
11 September 2026
NCT07807722 clinical landscape for EGFR-mutated non-small Cell Lung Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
Read →
IBI3046 in Obesity: NCT07809945 Clinical Landscape Report 2026
9 min read
IBI3046 in Obesity: NCT07809945 Clinical Landscape Report 2026
11 September 2026
NCT07809945 clinical landscape for Obesity: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Ublituximab in Myasthenia Gravis: NCT07673744 Clinical Landscape Report 2026
9 min read
Ublituximab in Myasthenia Gravis: NCT07673744 Clinical Landscape Report 2026
11 September 2026
NCT07673744 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
VV169 in Relapse multiple myeloma: NCT07802717 Clinical Landscape Report 2026
9 min read
VV169 in Relapse multiple myeloma: NCT07802717 Clinical Landscape Report 2026
11 September 2026
NCT07802717 clinical landscape for Relapse multiple myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Efimosfermin alfa in Metabolic Dysfunction Associated Steatohepatitis: NCT07701993 Clinical Landscape Report 2026
9 min read
Efimosfermin alfa in Metabolic Dysfunction Associated Steatohepatitis: NCT07701993 Clinical Landscape Report 2026
11 September 2026
NCT07701993 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
Read →
Indapamide in Multiple Sclerosis, Secondary Progressive: NCT07765212 Clinical Landscape Report 2026
9 min read
Indapamide in Multiple Sclerosis, Secondary Progressive: NCT07765212 Clinical Landscape Report 2026
11 September 2026
NCT07765212 clinical landscape for Multiple Sclerosis, Secondary Progressive: endpoints, sponsor, phase, geography, readouts, asset context and development w…
Read →
Temozolomide in Glioblastoma Multiforme: NCT07754734 Clinical Landscape Report 2026
9 min read
Temozolomide in Glioblastoma Multiforme: NCT07754734 Clinical Landscape Report 2026
11 September 2026
NCT07754734 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →